SEATTLE, May 9, 2013 /PRNewswire/ -- Plandai
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced a
distribution agreement which grants Natural Products the exclusive
rights in South Africa to develop
and market a weight management product using Plandai's Phytofare™
Catechin Extract. Natural Products specializes in producing
and selling Maxi™ nutraceuticals through an Internet client base
and directly to pharmacists and wellness retailers in South Africa.
Plandai's Phytofare™ Catechin Extract is processed to deliver a
highly bioavailable, antioxidant-rich material to a level many
times that of other green tea extracts available on the
market. Research has shown that green tea gallate catechins
are extremely active antioxidants and in a bioavailable form, are
able to protect the red and white blood cells against attack. While
not a cure, Phytofare™ Catechin Extract offers meaningful disease
prevention, particularly for patients suffering from a compromised
immune system, through infections, viruses, malaria and other
parasitic infections.
Green tea has long been recognized for its weight management
benefits including fat reduction, increased metabolism and improved
endurance during exercise. These benefits will be the focus
of the weight loss product using Phytofare™ Catechin Extract.
"Natural Products is a dynamic and innovative South African
company, and we believe it will excel in developing and marketing a
weight loss product using Phytofare™ Catechin Extract," said
Callum Baylis-Duffield,
Vice-President and Global Director, Marketing Sales for Plandai
Biotechnology.
"We are excited to have the opportunity to work with Plandai on
the development of this weight management product and believe it
has tremendous potential in the South
Africa market," said Warren
Booth of Natural Products."
In published USDA studies, Plandai's proprietary plant extracts,
including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex
and Phytofare™ Carotenoid Extract, have shown to have improved
bioavailability – the degree to which a substance becomes available
to the target tissue after administration – of between 60-80%, far
exceeding anything available today. Superior levels of
bioavailability simply mean that the body can actually receive the
benefits promised on the product label.
The Company believes that its technology is the foundation for
creating an entirely new family of drugs that can treat a multitude
of diseases and conditions safely and affordably using
naturally-derived extracts.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries develop highly
bioavailable; phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandai Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South
Africa, to producing its patented Phytofare™ extracts
in-house, allowing the Company to guarantee the continuity of
supply as well as quality control throughout the entire
process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical, and
pharmaceutical. For more information, please visit
http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandai's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandai is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaibiotech.com
SOURCE Plandai Biotechnology, Inc.